Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

676 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.
Coerver E, Schoof L, Hogenboom L, Wessels M, van Ruyven P, van Samkar A, Mostert J, van Kempen Z, van Oosten BW, Wokke BH, Tallantyre E, Myhr KM, Torkildsen O, Killestein J, Smets I, Strijbis E. Coerver E, et al. Among authors: wessels m. Mult Scler Relat Disord. 2024 Nov;91:105900. doi: 10.1016/j.msard.2024.105900. Epub 2024 Sep 28. Mult Scler Relat Disord. 2024. PMID: 39369631 Free article.
Natalizumab discontinuation in a Dutch real-world cohort.
Coerver EME, Wessels MHJ, van Lierop ZYG, van Kempen ZLE, Killestein J, Strijbis EMM. Coerver EME, et al. Among authors: wessels mhj. Mult Scler Relat Disord. 2021 Jul;52:102974. doi: 10.1016/j.msard.2021.102974. Epub 2021 Apr 24. Mult Scler Relat Disord. 2021. PMID: 33990055
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.
Coerver EME, Bourass A, Wessels MHJ, van Kempen ZLE, Jasperse MMS, Tonino BAR, Barkhof F, Mostert J, Uitdehaag BMJ, Killestein J, Strijbis EMM. Coerver EME, et al. Among authors: wessels mhj. Mult Scler Relat Disord. 2023 Jun;74:104706. doi: 10.1016/j.msard.2023.104706. Epub 2023 Apr 3. Mult Scler Relat Disord. 2023. PMID: 37068370 Free article.
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Toorop AA, Wessels MHJ, Gelissen LMY, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert JP, Wokke BHA, Kalkers NF, Hoogervorst ELJ, van Eijk JJJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, van Dijk GW, Bouvy WH, Strijbis EMM, van Oosten BW, de Jong BA, Lissenberg-Witte BI, Rispens T, Uitdehaag BMJ, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: wessels mhj. J Neurol Sci. 2024 Jul 15;462:123102. doi: 10.1016/j.jns.2024.123102. Epub 2024 Jun 22. J Neurol Sci. 2024. PMID: 38925067 Free article. Clinical Trial.
Influence of Distraction Factors on Performance in Laparoscopic Surgery in Immersive Virtual Reality: Study Protocol of a Cross-Over Trial in Medical Students and Residents-DisLapVR.
Hanke L, Schulte R, Boedecker C, Huettl F, Saalfeld P, Chheang V, Wessels M, von Castell C, Hecht H, Hansen C, Lang H, Huber T. Hanke L, et al. Among authors: wessels m. JMIR Res Protoc. 2024 Nov 5;13:e59014. doi: 10.2196/59014. JMIR Res Protoc. 2024. PMID: 39500487 Free PMC article.
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Toorop AA, Wessels MH, Boonkamp L, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Strijbis EM, van Oosten BW, de Jong BA, Uitdehaag BM, Rispens T, Killestein J, van Kempen ZL, Teunissen CE. Toorop AA, et al. Among authors: wessels mh. Mult Scler. 2024 Nov;30(13):1683-1688. doi: 10.1177/13524585241293940. Epub 2024 Nov 4. Mult Scler. 2024. PMID: 39494701 Free PMC article.
Effectiveness of transitional care in Inflammatory Bowel Disease; Development, Validation, and Initial outcomes of a Transition Success Score.
van Gaalen MA, van Pieterson M, Waaijenberg P, Kindermann A, Wolters VM, Dijkstra A, van Wering H, Wessels M, de Ridder L, Rizopoulos D, Derikx CLA, Escher JC. van Gaalen MA, et al. Among authors: wessels m. J Crohns Colitis. 2024 Nov 2:jjae166. doi: 10.1093/ecco-jcc/jjae166. Online ahead of print. J Crohns Colitis. 2024. PMID: 39487645
Search for the Exclusive W Boson Hadronic Decays W^{±}→π^{±}γ, W^{±}→K^{±}γ and W^{±}→ρ^{±}γ with the ATLAS Detector.
Aad G, Abbott B, Abeling K, Abicht NJ, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Acharya BS, Adam Bourdarios C, Adamczyk L, Addepalli SV, Addison MJ, Adelman J, Adiguzel A, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Ahmad A, Ahmadov F, Ahmed WS, Ahuja S, Ai X, Aielli G, Aikot A, Ait Tamlihat M, Aitbenchikh B, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Akiyama D, Akolkar NN, Aktas S, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Albouy GL, Alderweireldt S, Alegria ZL, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi F, Algren M, Alhroob M, Ali B, Ali HMJ, Ali S, Alibocus SW, Aliev M, Alimonti G, Alkakhi W, Allaire C, Allbrooke BMM, Allen JF, Allendes Flores CA, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alvarez Estevez M, Alvarez Fernandez A, Alves Cardoso M, Alviggi MG, Aly M, Amaral Coutinho Y, Ambler A, Amelung C, Amerl M, Ames CG, Amidei D, Amor Dos Santos SP, Amos KR, Ananiev V, Anastopoulos C, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Anulli F, Aoki M, Aoki T, Aparisi Pozo JA, Aparo MA, Aperio Bella L, A… See abstract for full author list ➔ Aad G, et al. Among authors: wessels m. Phys Rev Lett. 2024 Oct 18;133(16):161804. doi: 10.1103/PhysRevLett.133.161804. Phys Rev Lett. 2024. PMID: 39485985
676 results